Lotus Pharmaceutical Co (TPE:1795) Cyclically Adjusted PS Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1795 Lotus Pharmaceutical Co Ltd TPE:1795
76 GF Score
Price NT$176.50
GF Value NT$462.94
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lotus Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lotus Pharmaceutical Co  (TPE:1795) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lotus Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Lotus Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Lotus Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Lotus Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.15 6.60 6.36 5.52 5.16

Lotus Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.39 4.26 4.85 5.16 0.00

TPE:1795 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lotus Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lotus Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lotus Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TPE:1795
76GF Score
Lotus Pharmaceutical Co Ltd TPE:1795
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lotus Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lotus Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Lotus Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=33.025/330.2130*330.2130
=33.025

Current CPI (Mar. 2026) = 330.2130.

Lotus Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6.636 241.018 9.092
201609 6.081 241.428 8.317
201612 6.211 241.432 8.495
201703 6.029 243.801 8.166
201706 6.785 244.955 9.147
201709 6.523 246.819 8.727
201712 7.687 246.524 10.297
201803 6.254 249.554 8.275
201806 6.776 251.989 8.879
201809 6.571 252.439 8.595
201812 7.232 251.233 9.506
201903 9.163 254.202 11.903
201906 8.464 256.143 10.912
201909 8.287 256.759 10.658
201912 13.179 256.974 16.935
202003 8.368 258.115 10.705
202006 11.026 257.797 14.123
202009 11.909 260.280 15.109
202012 12.823 260.474 16.256
202103 13.637 264.877 17.001
202106 13.482 271.696 16.386
202109 11.677 274.310 14.057
202112 10.693 278.802 12.665
202203 12.129 287.504 13.931
202206 11.103 296.311 12.373
202209 20.553 296.808 22.866
202212 12.070 296.797 13.429
202303 17.258 301.836 18.881
202306 16.984 305.109 18.381
202309 17.435 307.789 18.705
202312 13.011 306.746 14.006
202403 15.963 312.332 16.877
202406 18.023 314.175 18.943
202409 19.899 315.301 20.840
202412 16.652 315.605 17.423
202503 17.885 319.799 18.467
202506 18.186 322.561 18.617
202509 18.322 324.800 18.627
202512 23.863 324.054 24.317
202603 33.025 330.213 33.025

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lotus Pharmaceutical Co (TPE:1795) Overvalued in 2026?

Based on GuruFocus' analysis, Lotus Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$176.50 is trading 61.9% below its estimated GF Value™ of NT$462.94. GuruFocus considers Lotus Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for TPE:1795:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$462.94 vs. price of NT$176.50 (61.9% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the TPE:1795 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lotus Pharmaceutical Co Business Description

Address Song Ren Road, No. 277, 17th Floor, Xin Yi District, Taipei, TWN, 11046
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.
76GF Score

Get the complete analysis for TPE:1795

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$176.50
Price
NT$462.94
GF Value